Abstract
Dextran sulfate sodium (DSS)-induced colitis is frequently used as an animal model of inflammatory bowel disease (IBD). However, first-line therapeutic agents, such as the corticosteroid prednisolone (PSL), show poor efficacy or even worsen colitis in the rodent model. Species specific differences in inflammatory/immune mechanisms between humans and rodents could be potential sources of this issue. Nonhuman primates (NHP) are phylogenetically closer to humans than rodents and are useful in investigating mucosal immunity. In the present study, a NHP model of chronic colitis was developed and the effect of PSL and the alpha-integrin blocking antibody vedolizumab (VED) on remission was assessed in this model.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
